CD79A and COVID-19: In this secondary analysis of our double-blind, placebo-controlled RCT including 128 (34%) of the outpatients with COVID-19 enrolled in the COnV-ert study, we observed that intravenous infusion of 1 unit of MB-treated high titer CCP significantly increased anti-SARS-CoV-2 IgG and IgG1 (to RBD and S), IgG3 (to S and S2), and IgG avidity in recipients at day 7 after infusion without an increase in IgA, IgM, IgG2, IgG4, or neutralizing antibodies.